Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06695494

Enabling Genomic Testing in Cancer of Unknown Primary

Enabling Genomic Testing in Cancer of Unknown Primary — Recruiting • Oncology • NCT06695494.

📅 25 Mar 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06695494
Sponsor
The Christie NHS Foundation Trust
Start
2024-08-15
ClinicaliQ Trial Snapshot
  • Enabling Genomic Testing in Cancer of Unknown Primary — Recruiting • Oncology • NCT06695494.
  • Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a….
  • Sponsor: The Christie NHS Foundation Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a median survival of 6-9 months. There is a higher than average incidence of CUP in the North West (NW) of England (population of 7.4 million). Precision medicine has transformed treatment strategies in known tumour types, however in CUP there remains an urgent need to better understand CUP molecular…

Eligibility Snapshot
  • : 1. Aged 16 years or over 2. Written informed consent according to ICH/GCP and national regulations 3. ECOG Performance status 0-2 4. Confirmed diagnosis of CUP as per the ESMO guidelines. Patients must have; 1. The local pathology reports confirming compatibility with CUP diagnosis and the associated slides used for the diagnosis 2. Discussion at a local CUP MDT confirming diagnosis 5. Availability of archival tumour histological report 6. Willingness to provide blood samples on up to two occasions during the study

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Emotional TV plea for cancer research leads to meeting with PM
Oncology · BBC Health · 15 Oct 2026
A Scottish athlete with inoperable brain tumours has successfully lobbied for increased investment in brain cancer research, highlighting the clinical need for…
View brief →
Clinical Brief
From weeks to hours – the rapid new test transforming brain tumour diagnosis
Oncology · BBC Health · 24 Sep 2026
Brain tumour diagnosis now achievable in hours rather than weeks, enabling faster treatment initiation and reducing patient anxiety Rapid testing allows earlier…
View brief →
Clinical Brief
New hope for breast cancer patients as life-extending drug now on NHS in England
Oncology · BBC Health · 16 Sep 2026
Enhertu is now available on the NHS in England, extending median overall survival by approximately seven months in eligible breast cancer patients…
View brief →
Clinical Brief
‘I have chronic cancer but I’m not going to die’ – BBC presenter Maryam Moshiri
Oncology · BBC Health · 07 Sep 2026
Polycythaemia vera should be considered in patients with unexplained blood count abnormalities; routine GP testing can identify the condition before symptomatic presentation…
View brief →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →